Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure: a Randomized Clinical Trial

Who is this study for? Adult patients with Anal Fissures
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

No study to date has compared topical DTZ to MEBO ointment in the treatment of anal fissure. Therefore, the present study aims to compare the efficacy and safety of DTZ to MEBO in the treatment of acute anal fissure. The investigators propose to conduct a comparative randomized clinical study. In this study, the investigators will compare patients with acute anal fissure receiving MEBO ointment vs Topical DTZ ointment vs a combination of MEBO and DTZ ointment. Hypothesis: MEBO in combination with DTZ is more effective than DTZ or MEBO alone in the treatment of acute anal fissure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects must be 18 years and above.

‣ Subjects with 3 months (90 days) or less history of painful anal fissure (AF), prior to screening, where AF-related pain-associated with, or following, defecation is experienced at least twice a week during the symptomatic phase, with pain scores at an average of ≥ 3 on an 11-point NRS (Numerical Rating Scale, range 0-10 where 0 = no pain and 10 = worst pain imaginable).

⁃ Subjects with an average of ≥4 on an 11-point NRS during the screening phase for worst anal pain associated with, or following, defecation for the most recent 3 days on which the subject has defecated.

⁃ Subjects with evidence of a radial fissure, with induration at the edges, seen on anal examination.

⁃ Willing to stop all other concomitant topical preparations applied perianally prior to commencing study treatment, and throughout the study. There will be a washout period of at least 2 weeks prior to commencing the study for subjects who were using other concomitant topical preparations applied perianally.

⁃ Able to give consent

Locations
Other Locations
Lebanon
American University of Beirut
RECRUITING
Beirut
Contact Information
Primary
Eman Sbaity, MD
es25@aub.edu.lb
+961-76-110882
Backup
Mohamad Hadi El Charif, MD
mohamadhadi.elcharif@gmail.com
+961-3-771917
Time Frame
Start Date: 2019-12-01
Estimated Completion Date: 2026-01-30
Participants
Target number of participants: 183
Treatments
Experimental: DTZ arm
The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.
Experimental: MEBO arm
The second group of patients will apply topical DTZ ointment peri-anally 3 times daily for 6 weeks.
Experimental: MEBO and DTZ arm
The third group will apply a combination of MEBO and DTZ ointment peri-anally 3 times daily for 6 weeks. Those who fail therapy (meaning they report no pain improvement after two weeks of treatment) from either the MEBO or the Diltiazem arm will be switched to the combination arm. If they also fail to improve after two weeks on the treatment arm, then they will be offered surgery. If the patient refuses to switch to the combination arm and wishes to proceed to surgery immediately, then the patient will be directed to surgery.
Related Therapeutic Areas
Sponsors
Leads: American University of Beirut Medical Center

This content was sourced from clinicaltrials.gov